FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
Medscape2d
FDA Approves Dupilumab as Add-On for COPD
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...
Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80%
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
framinghamsource2d
New Pulmonary Rehabilitation Program at MetroWest Medical Center is a Breath of Fresh Air for Those with Chronic Lung Disease
For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...
The American Journal of Managed Care5d
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Too Old to Operate2d
VRE Faecium Pneumonia Following Aspiration in a Patient with COPD
The following is a summary of “Vancomycin-resistant Enterococcus (VRE) Pneumonia in a Patient With Advanced Chronic ...
malaymail on MSN1h
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Medscape1d
Cilomilast: Orally Active Selective Phosphodiesterase-4 Inhibitor for Treatment of Chronic Obstructive Pulmonary Disease
and airway remodeling associated with chronic obstructive pulmonary disease (COPD). Selective PDE4 inhibition is proposed to maximize the antiinflammatory effects of PDE inhibition while ...
WebMD18h
Dupixent Gets FDA Approval for COPD
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.